# NCT06128551 (NCT06128551)

> Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06128551
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions: Elironrasib; Daraxonrasib
- Enrollment: 534
- Primary outcome: Number of patients with adverse events (AEs) in Phase 1b
- Primary outcome: Changes in vital signs in Phase 1b
- Primary outcome: Changes in clinical laboratory test values in Phase 1b
- Primary outcome: Dose Limiting Toxicities in Phase 1b
- Primary outcome: Changes in ECGs in Phase 1b
- Primary outcome: Overall Response Rate (ORR) in Phase 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06128551